Actelion Ltd (ALIOF) 123.1000 $ALIOF
Seattle Genetics Up on Narrower-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 3:20PM CDT
Seattle Genetics reported second-quarter loss per share of 14 cents, narrower than the Zacks Consensus Estimate of a loss of 22 cents.
Alkermes Reports Loss in Q2 on Higher Costs, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 2:40PM CDT
Alkermes (ALKS) incurred loss in the quarter due to higher expenses.
ImmunoGen Q4 Loss Narrower than Expected, Provides Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 1:50PM CDT
ImmunoGen (IMGN) reported fourth quarter loss of 31 cents per share, narrower than the Zacks Consensus Estimate of a loss of 36 cents.
Affymetrix Down despite Q2 Earnings and Revenues Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 12:10PM CDT
Affymetrix Inc. (AFFX) upgraded its previously announced revenue and EBITDA guidance for 2014.
Pacira Up on Narrower-than-Expected Loss, Revenue Beat in Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 11:10AM CDT
Pacira's second-quarter 2014 loss of 14 cents per share was well below the Zacks Consensus Estimate of a loss of 24 cents and the year-ago figure of 42 cents per share.
Momenta Posts Narrower Q2 Loss, Revenues Up Y/Y, Shares Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 10:50AM CDT
Momenta Pharmaceuticals Inc. (MNTA) reported second-quarter 2014 net loss per share of 51 cents, wider than the Zacks Consensus Estimate of a loss of 49 cents but narrower than the year-ago loss of 57 cents.
Acorda Beats on Q2 Earnings & Revenues, Maintains View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Aug 04, 8:20AM CDT
Acorda (ACOR) recorded an improvement in Ampyra revenues and continues to expect Ampyra sales in the range of $328 million - $335 million.
Cambrex Corporation (CBM) in Focus: Stock Up 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 7:44AM CDT
Cambrex Corporation. (CBM) was a big mover last session, as the company saw its shares rise over 7% on the day.
Pharmacyclics Incurs Q2 Loss, Revenues Up on Imbruvica Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 4:10PM CDT
Pharmacyclics (PCYC) reported better than expected revenues on strong Imbruvica sales.
Synageva Slips on Wider-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 3:30PM CDT
Synageva BioPharma Corp's second quarter 2014 loss came in at $1.52 per share, much wider than the year-ago loss of 81 cents per share and the Zacks Consensus Estimate of a loss of $1.37.
Endo International Beats on Q2 Earnings & Sales, Guidance Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 2:36PM CDT
Endo (ENDP) reported higher-than-expected earnings and revenues in the quarter.
Incyte Posts Wider-than-Expected Q2 Loss, Raises Sales View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 10:17AM CDT
Incyte Corporation (INCY) reported a loss of 22 cents per share in the second quarter of 2014, significantly wider than the Zacks Consensus Estimate of a loss of 9 cents.
United Therapeutics (UTHR) Up on Q2 Earnings & Revenue Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 12:20PM CDT
Lower costs and higher revenues helped United Therapeutics (UTHR) deliver better-than-expected earnings.
Ultragenyx Pharmaceutical (RARE) Jumps: Stock Rises 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 8:39AM CDT
Ultragenyx Pharmaceutical (RARE) was a big mover last session, as its shares rose over 5% on the day.
Sarepta Therapeutics (SRPT) Soars: Stock Rises 12.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 8:39AM CDT
Sarepta Therapeutics, Inc. (SRPT) was a big mover last session, as its shares rose nearly 13% on the day.
Strength Seen in Aegerion Pharmaceuticals (AEGR): Stock Shoots up 16.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 7:44AM CDT
Aegerion Pharmaceuticals, Inc. (AEGR) was a big mover last session, as the company saw its shares surge over 16% on the day.
Regeneron's Eylea Gets FDA Nod for Diabetic Macular Edema - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 6:00PM CDT
Regeneron Pharmaceuticals, Inc.'s (REGN) eye drug Eylea received FDA approval for a third indication: the treatment of diabetic macular edema.
Aegerion Q2 Loss Narrower than Expected, 2014 View Retained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 2:15PM CDT
Aegerion (AEGR) reported second quarter 2014 net loss per share of 33 cents, narrower than the Zacks Consensus Estimate of a loss of 42 cents.
AMAG Pharmaceuticals Q2 Loss Narrows as Feraheme Sales Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 12:50PM CDT
AMAG's (AMAG) second quarter loss narrowed on the back of increased Feraheme sales.
Qiagen Reports In-line Earnings, Beats on Revenues in Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 12:20PM CDT
Qiagen N.V. (QGEN) reported second-quarter 2014 adjusted EPS of 25 cents.
Seattle Genetics Up on Narrower-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 3:20PM CDT
Seattle Genetics reported second-quarter loss per share of 14 cents, narrower than the Zacks Consensus Estimate of a loss of 22 cents.
Alkermes Reports Loss in Q2 on Higher Costs, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 2:40PM CDT
Alkermes (ALKS) incurred loss in the quarter due to higher expenses.
ImmunoGen Q4 Loss Narrower than Expected, Provides Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 1:50PM CDT
ImmunoGen (IMGN) reported fourth quarter loss of 31 cents per share, narrower than the Zacks Consensus Estimate of a loss of 36 cents.
Affymetrix Down despite Q2 Earnings and Revenues Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 12:10PM CDT
Affymetrix Inc. (AFFX) upgraded its previously announced revenue and EBITDA guidance for 2014.
Pacira Up on Narrower-than-Expected Loss, Revenue Beat in Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 11:10AM CDT
Pacira's second-quarter 2014 loss of 14 cents per share was well below the Zacks Consensus Estimate of a loss of 24 cents and the year-ago figure of 42 cents per share.
Momenta Posts Narrower Q2 Loss, Revenues Up Y/Y, Shares Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 10:50AM CDT
Momenta Pharmaceuticals Inc. (MNTA) reported second-quarter 2014 net loss per share of 51 cents, wider than the Zacks Consensus Estimate of a loss of 49 cents but narrower than the year-ago loss of 57 cents.
Acorda Beats on Q2 Earnings & Revenues, Maintains View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Aug 04, 8:20AM CDT
Acorda (ACOR) recorded an improvement in Ampyra revenues and continues to expect Ampyra sales in the range of $328 million - $335 million.
Cambrex Corporation (CBM) in Focus: Stock Up 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 7:44AM CDT
Cambrex Corporation. (CBM) was a big mover last session, as the company saw its shares rise over 7% on the day.
Pharmacyclics Incurs Q2 Loss, Revenues Up on Imbruvica Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 4:10PM CDT
Pharmacyclics (PCYC) reported better than expected revenues on strong Imbruvica sales.
Synageva Slips on Wider-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 3:30PM CDT
Synageva BioPharma Corp's second quarter 2014 loss came in at $1.52 per share, much wider than the year-ago loss of 81 cents per share and the Zacks Consensus Estimate of a loss of $1.37.
Endo International Beats on Q2 Earnings & Sales, Guidance Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 2:36PM CDT
Endo (ENDP) reported higher-than-expected earnings and revenues in the quarter.
Incyte Posts Wider-than-Expected Q2 Loss, Raises Sales View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 10:17AM CDT
Incyte Corporation (INCY) reported a loss of 22 cents per share in the second quarter of 2014, significantly wider than the Zacks Consensus Estimate of a loss of 9 cents.
United Therapeutics (UTHR) Up on Q2 Earnings & Revenue Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 12:20PM CDT
Lower costs and higher revenues helped United Therapeutics (UTHR) deliver better-than-expected earnings.
Ultragenyx Pharmaceutical (RARE) Jumps: Stock Rises 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 8:39AM CDT
Ultragenyx Pharmaceutical (RARE) was a big mover last session, as its shares rose over 5% on the day.
Sarepta Therapeutics (SRPT) Soars: Stock Rises 12.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 8:39AM CDT
Sarepta Therapeutics, Inc. (SRPT) was a big mover last session, as its shares rose nearly 13% on the day.
Strength Seen in Aegerion Pharmaceuticals (AEGR): Stock Shoots up 16.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 7:44AM CDT
Aegerion Pharmaceuticals, Inc. (AEGR) was a big mover last session, as the company saw its shares surge over 16% on the day.
Regeneron's Eylea Gets FDA Nod for Diabetic Macular Edema - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 6:00PM CDT
Regeneron Pharmaceuticals, Inc.'s (REGN) eye drug Eylea received FDA approval for a third indication: the treatment of diabetic macular edema.
Aegerion Q2 Loss Narrower than Expected, 2014 View Retained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 2:15PM CDT
Aegerion (AEGR) reported second quarter 2014 net loss per share of 33 cents, narrower than the Zacks Consensus Estimate of a loss of 42 cents.
AMAG Pharmaceuticals Q2 Loss Narrows as Feraheme Sales Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 12:50PM CDT
AMAG's (AMAG) second quarter loss narrowed on the back of increased Feraheme sales.
Qiagen Reports In-line Earnings, Beats on Revenues in Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 12:20PM CDT
Qiagen N.V. (QGEN) reported second-quarter 2014 adjusted EPS of 25 cents.
